Loading stock data…
SNY
$46.08-0.50 (-1.07%)
Market ClosedLast close May 1
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sanofi in the Healthcare sector is trading at $46.08. The stock is currently 17% below its 52-week high of $55.29, remaining 4.1% below its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why SNY maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$46.08
Potential Upside
3.3%
Whystock Fair Value$47.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$55.90+21.3%
Range$51.00 – $63.00
Fundamentals
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$113.52B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.91
Beta
Defensive asset. Lower volatility than the S&P 500.
0.32
Div Yield
Strong income play. Yield provides a meaningful total return floor.
516.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.79%
Volume
Today's trading volume
2.21M
Recent News
A Look At Novavax (NVAX) Valuation As It Shifts To Licensing And Awaits Combo Vaccine Data
Novavax (NVAX) is in focus after outlining a move toward a licensing and royalty model, supported by partnerships with Sanofi and Pfizer, while investors watch for a Phase 3 COVID influenza combo readout. See our latest analysis for Novavax. The licensing pivot and upcoming COVID influenza combo catalyst come after a mixed period for investors, with a 12.76% year-to-date share price return alongside a 25.43% one-year total shareholder return, but a very large five-year total shareholder loss...
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.
Sanofi (ENXTPA:SAN) Valuation After Cenrifki Progress New CEO Appointment And Stronger Dupixent Momentum
Why Sanofi’s recent news flow matters for shareholders Sanofi (ENXTPA:SAN) has packed several key updates into late April, from appointing Belén Garijo as Chief Executive Officer and refreshing its board, to advancing multiple medicines and reaffirming its 2026 earnings guidance. See our latest analysis for Sanofi. Despite a steady flow of product approvals, regulatory milestones and leadership changes, Sanofi’s share price has been relatively muted, with a 1 day share price return of 1.92%...
Kymera Therapeutics Q1 Earnings Call Highlights
Kymera Therapeutics (NASDAQ:KYMR) highlighted progress across its clinical-stage pipeline and provided a financial update during its first-quarter 2026 results call, with executives emphasizing execution of ongoing Phase 2b studies for KT-621 and upcoming clinical readouts for the IRF5 degrader KT-5
Is Novavax, Inc. (NVAX) A Good Stock To Buy Now?
Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on NVAX. Novavax, Inc.’s share was trading at $8.67 as of April 20th. NVAX’s trailing P/E was 3.36 according to Yahoo Finance. Novavax, Inc., a biotechnology company, engages in the discovery, development, […]